Neurobehavioral Disorders
Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Neurobehavioral Disorders
In a recent survey, more than half the college students with ADHD had at least 1 psychiatric disorder. The recent WHO World Mental Health Survey of college students assessed comorbidities in more than 15,000 college freshmen across 9 countries.
Neurobehavioral Disorders
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Neurobehavioral Disorders
Universal school-based MDD screening increases identification of adolescents with MDD symptoms and initiation of treatment.
Neurobehavioral Disorders
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
Neurobehavioral Disorders
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Neurobehavioral Disorders
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
Neurobehavioral Disorders
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Neurobehavioral Disorders
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
Neurobehavioral Disorders
For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.
